The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Gene Editing for CEP290 -Associated Retinal Degeneration
Open accessAbstract
Background CEP290 -associated inherited retinal degeneration causes severe early-onset vision loss due to pathogenic variants in CEP290 . EDIT-101 is a clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9) gene-editing complex designed to treat inherited retinal degeneration caused by a specific damaging variant in intron 26 of CEP290 (IVS26 variant). Methods We performed a phase 1–2, open-label, single-ascending-dose study in which persons 3 years of age or older with CEP290 -associated inherited retinal degeneration caused by a homozygous or compound heterozygous IVS26 variant received a subretinal injection of EDIT-101 in the worse (study) eye. The primary outcome was safety, which included adverse events and dose-limiting toxic effects. Key secondary efficacy outcomes were the change from baseline in the best corrected visual acuity, the retinal sensitivity detected with the use of full-field stimulus testing (FST), the score on the Ora–Visual Navigation Challenge mobility test, and the vision-related quality-of-life score on the National Eye Institute Visual Function Questionnaire–25 (in adults) or the Children’s Visual Function Questionnaire (in children). Results EDIT-101 was injected in 12 adults 17 to 63 years of age (median, 37 years) at a low dose (in 2 participants), an intermediate dose (in 5), or a high dose (in 5) and in 2 children 9 and 14 years of age at the intermediate dose. At baseline, the median best corrected visual acuity in the study eye was 2.4 log 10 of the minimum angle of resolution (range, 3.9 to 0.6). No serious adverse events related to the treatment or procedure and no dose-limiting toxic effects were recorded. Six participants had a meaningful improvement from baseline in cone-mediated vision as assessed with the use of FST, of whom 5 had improvement in at least one other key secondary outcome. Nine participants (64%) had a meaningful improvement from baseline in the best corrected visual acuity, the sensitivity to red light as measured with FST, or the score on the mobility test. Six participants had a meaningful improvement from baseline in the vision-related quality-of-life score. Conclusions The safety profile and improvements in photoreceptor function after EDIT-101 treatment in this small phase 1–2 study support further research of in vivo CRISPR-Cas9 gene editing to treat inherited retinal degenerations due to the IVS26 variant of CEP290 and other genetic causes. (Funded by Editas Medicine and others; BRILLIANCE ClinicalTrials.gov number, NCT03872479 .)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The doses of AAV vectors that have been used in retinal gene therapy trials have ranged from ~1 × 10 8 (Heier et al., 2017) up to ~3 × 10 12 vg/eye (Yang et al., 2022; Pierce et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Pierce et al., 2024
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a groundbreaking first-in-human study, EDIT-101 (Editas, Cambridge, Massachusetts, USA), comprising an AAV5 vector encoding Staphylococcus aureus Cas9 and two guide RNAs targeting CEP290 associated with LCA, was well tolerated at relatively high vector doses (Pierce et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Pierce et al., 2024
In the citing paper
“In humans, EDIT-101 has demonstrated a positive safety profile and variable effectiveness of visual functional outcomes (retinal sensitivity, visual acuity, Ora–Visual Navigation Challenge) in Phase 1/2 of a small cohort of 14 participants ( NCT03872479 ), 64 which is ongoing with a larger cohort (34 participants) to confirm efficacy ( Table 1 ).”
From Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches (2025) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Mutations in the CEP290 (NPHP6) Gene Are a Frequent Cause of Leber Congenital Amaurosis
den Hollander, A. I., Koenekoop, R. K., Yzer, S., López, I., Arends, M. L., Voesenek, K., Zonneveld, M. N., Strom, T. M., Meitinger, T., Brunner, H. G., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/507318 · Cited by 669
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Self-citationWorldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases
Hanany, M., Rivolta, C., & Sharon, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913179117 · Cited by 408
Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0763-1 · Cited by 368
Self-citationParfitt, D. A., Lane, A., Ramsden, C. M., Carr, A. F., Munro, P., Jovanovic, K., Schwarz, N., Kanuga, N., Muthiah, M. N., Hull, S., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.03.021 · Cited by 314
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium *
Csaky, K. G., Richman, E. A., & Ferris, F. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1132 · Cited by 265
Clinical Characteristics and Current Therapies for Inherited Retinal DegenerationsPreprint
Sahel, J., Marazova, K., & Audo, I. S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017111 · Cited by 249
Perrault, I., Delphin, N., Hanein, S., Gerber, S., Dufier, J., Roche, O., Defoort‐Dhellemmes, S., Dollfus, H., Fazzi, E., Münnich, A., et al. (2007) · Human Mutation · doi:10.1002/humu.9485 · Cited by 239
Cideciyan, A. V., Jacobson, S. G., Drack, A. V., Ho, A. C., Charng, J., Garafalo, A. V., Román, A. J., Sumaroka, A., Han, I. C., Hochstedler, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0295-0 · Cited by 223
Jeffery, R. C. H., Mukhtar, S. A., McAllister, I. L., Morgan, W. H., Mackey, D. A., & Chen, F. K. (2021) · Ophthalmic Genetics · doi:10.1080/13816810.2021.1913610 · Cited by 199
Cideciyan, A. V., Alemán, T. S., Jacobson, S. G., Khanna, H., Sumaroka, A., Aguirre, G. K., Schwartz, S., Windsor, E. A. M., He, S., Chang, B., et al. (2007) · Human Mutation · doi:10.1002/humu.20565 · Cited by 157
Intravitreal Sepofarsen for Leber Congenital Amaurosis Type 10 (LCA10)
Russell, S. R., Drack, A. V., Cideciyan, A. V., Jacobson, S. G., Leroy, B. P., Cauwenbergh, C. V., Ho, A. C., Dumitrescu, A. V., Han, I. C., Martin, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-022-01755-w · Cited by 154
Menke, M. N., Dabov, S., Knecht, P. B., & Sturm, V. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.09.005 · Cited by 135
CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype
Burnight, E. R., Wiley, L. A., Drack, A. V., Braun, T. A., Anfinson, K. R., Kaalberg, E. E., Halder, J. A., Affatigato, L. M., Mullins, R. F., Stone, E. M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.39 · Cited by 128
Natural History of the Central Structural Abnormalities in Choroideremia
Alemán, T. S., Han, G., Serrano, L. W., Fuerst, N. M., Charlson, E. S., Pearson, D. J., Chung, D. C., Traband, A., Pan, W., Ying, G., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.10.022 · Cited by 119
Self-citationCtori, I., & Huntjens, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129005 · Cited by 112
The Berkeley Rudimentary Vision Test
Bailey, I. L., Jackson, A. J., Minto, H., Greer, R. B., & Chu, M. A. (2012) · Optometry and Vision Science · doi:10.1097/opx.0b013e318264e85a · Cited by 112
Validity and reliability of the Children’s Visual Function Questionnaire (CVFQ)
Birch, E. E., Cheng, C. S., & Felius, J. (2007) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2007.02.011 · Cited by 105
Leber’s Congenital Amaurosis: Current Concepts of Genotype-Phenotype Correlations
Huang, C.-H., Yang, C., Yang, C., Hou, Y., & Chen, T. (2021) · Genes · doi:10.3390/genes12081261 · Cited by 95
Klein, M., & Birch, D. G. (2009) · Documenta Ophthalmologica · doi:10.1007/s10633-009-9204-7 · Cited by 85
Advances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
Román, A. J., Cideciyan, A. V., Wu, V. F., Garafalo, A. V., & Jacobson, S. G. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101000 · Cited by 63
Lacy, G. D., Abalem, M. F., Andrews, C., Popova, L., Santos, E. P., Yu, G., Rakine, H. Y., Baig, N., Ehrlich, J. R., Fahim, A. T., et al. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.08.032 · Cited by 61
Zhang, W., Li, L., Su, Q., Gao, G., & Khanna, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.049 · Cited by 60
RDH12 Mutations Cause a Severe Retinal Degeneration With Relatively Spared Rod Function
Alemán, T. S., Uyhazi, K. E., Serrano, L. W., Vasireddy, V., Bowman, S. J., Ammar, M. J., Pearson, D. J., Maguire, A. M., & Bennett, J. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24708 · Cited by 59
Self-citationJacobson, S. G., Cideciyan, A. V., Sumaroka, A., Román, A. J., Charng, J., Lu, M., Choi, W., Sheplock, R., Świder, M., Kosyk, M. S., et al. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21560 · Cited by 58
Visual Acuity Changes in Patients With Leber Congenital Amaurosis and Mutations in CEP290
McAnany, J. J., Genead, M. A., Walia, S., Drack, A. V., Stone, E. M., Koenekoop, R. K., Traboulsi, E. I., Smith, A. S., Weleber, R. G., Jacobson, S. G., et al. (2013) · JAMA Ophthalmology · doi:10.1001/2013.jamaophthalmol.354 · Cited by 52
Jacobson, S. G., Cideciyan, A. V., Ho, A. C., Peshenko, I. V., Garafalo, A. V., Román, A. J., Sumaroka, A., Wu, V. F., Krishnan, A. K., Sheplock, R., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102409 · Cited by 45
Sumaroka, A., Garafalo, A. V., Semenov, E. P., Sheplock, R., Krishnan, A. K., Román, A. J., Jacobson, S. G., & Cideciyan, A. V. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-27156 · Cited by 38
Night vision restored in days after decades of congenital blindness
Jacobson, S. G., Cideciyan, A. V., Ho, A. C., Román, A. J., Wu, V. F., Garafalo, A. V., Sumaroka, A., Krishnan, A. K., Świder, M., Mascio, A. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105274 · Cited by 35
Collison, F. T., Park, J. C., Fishman, G. A., McAnany, J. J., & Stone, E. M. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17467 · Cited by 32
Boye, S. E., Huang, W.-C., Román, A. J., Sumaroka, A., Boye, S. L., Ryals, R. C., Olivares, M. B., Ruan, Q., Tucker, B. A., Stone, E. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092928 · Cited by 31
PSYCHOPHYSICAL MEASUREMENT OF ROD AND CONE THRESHOLDS IN STARGARDT DISEASE WITH FULL-FIELD STIMULI
Collison, F. T., Fishman, G. A., McAnany, J. J., Zernant, J., & Allikmets, R. L. (2014) · Retina · doi:10.1097/iae.0000000000000144 · Cited by 29
Current Modalities for Low Vision Rehabilitation
Agarwal, R., & Tripathi, A. (2021) · Cureus · doi:10.7759/cureus.16561 · Cited by 21
Green, J., Tolley, C., Bentley, S., Arbuckle, R., Burstedt, M. S. I., Whelan, J., Holopigian, K., Stasi, K., Sloesen, B. J., Spera, C., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01275-4 · Cited by 20
Cideciyan, A. V., Jacobson, S. G., Ho, A. C., Krishnan, A. K., Román, A. J., Garafalo, A. V., Wu, V. F., Świder, M., Sumaroka, A., Cauwenbergh, C. V., et al. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100133 · Cited by 18
Pierce, E. A., Ashimatey, B. S., Jayasundera, T., Hoyng, C. B., Lam, B. L., Lorenz, B., Kim, K., Rashid, A., Myers, R., & Pennesi, M. E. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100483 · Cited by 7
Self-citationFleck-like lesions in CEP290-associated leber congenital amaurosis: a case series
Alemán, T. S., O'Neil, E. C., Uyhazi, K. E., Parchinski, K. M., Santos, A. J., Weber, M. L., Colclough, S. P., Billek, A. S., Zhu, X., Leroy, B. P., et al. (2022) · Ophthalmic Genetics · doi:10.1080/13816810.2022.2147960 · Cited by 3
Flagged first, then by citations
Research works printed but not linked: 1
- Pierce EA Ashimatey BS Jayasundera T et al. Twelve-month natural history study of CEP290-associated retinal degeneration. Ophthalmol Sci (in press) (https://www.ophthalmologyscience.org/article/S2666-9145(24)00019-8/pdf).
Cited by
Sorted by citations
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 152
Ling, S., Zhang, X., Dai, Y., Jiang, Z., Zhou, X., Lu, S., Qian, X., Liu, J., Selfjord, N., Şatır, T. M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01851-7 · Cited by 98
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Azeez, S. S., Hamad, R. S., Hamad, B., Shekha, M. S., & Bergsten, P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1509924 · Cited by 88
Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects
Cetin, B., Erendor, F., Ekşi, Y. E., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2025.10 · Cited by 80
Cavazza, A., Molina-Estévez, F. J., Reyes, Á. P., Ronco-Díaz, V., Naseem, A., Malenšek, Š., Pečan, P., Santini, A., Heredia, P., Aguilar-González, A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102457 · Cited by 78
Metadata
- Authors
- Pierce, E. A., Aleman, T. S., Jayasundera, K. T., Ashimatey, B. S., Kim, K., Rashid, A., Jaskolka, M. C., Myers, R. L., Lam, B. L., Bailey, S. T., Comander, J. I., Lauer, A. K., Maguire, A. M., & Pennesi, M. E.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- From the Ocular Genomics Institute, Department of Ophthalmology, Mass Eye and Ear and Harvard Medical School, Boston (E.A.P., J.I.C.), and Editas Medicine, Cambridge (B.S.A., K.K., A.R., M.C.J., R.L.M.) — both in Massachusetts; the Scheie Eye Institute and the Division of Ophthalmology of the Children’s Hospital of Philadelphia, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (T.S.A., A.M.M.); the University of Michigan Kellogg Eye Center, Ann Arbor (K.T.J.); the Bascom Palmer Eye Institute, University of Miami, Miami (B.L.L.); and the Casey Eye Institute, Oregon Health and Science University, Portland (S.T.B., A.K.L., M.E.P.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-06-06
- Volume
- 390
- Issue
- 21
- Pages
- 1972-1984
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11389875
- OpenAlex
- W4396676517
- Cited by
- 237
- References
- 41
- Citations by year
- 2026: 101 · 2025: 103 · 2024: 33
- FWCI
- 31.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Malcolm M. Marquis MD Endowed Fund for Innovation
- Research to Prevent Blindness
- Irene Heinz Given and John La Porte Given Endowment
- Hope For Vision
- National Eye Institute (P30 EY010572, P30 EY014104)
- Editas Medicine
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- CRISPR/Cas9 genome editing, subretinal injection, photoreceptor function, best-corrected visual acuity, retinal sensitivity, vision-related quality of life, children, compound heterozygosity
- MeSH terms
- Gene Editing, Adolescent, Adult, Antigens, Neoplasm, Cytoskeletal Proteins, Female, Humans, Male, Middle Aged, Quality of Life, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Cell Cycle Proteins, Young Adult, Injections, Intraocular, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
